Alec Stranahan
Stock Analyst at B of A Securities
(0.57)
# 4,051
Out of 4,984 analysts
35
Total ratings
30.43%
Success rate
-27.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $4.85 | +44.33% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $8.62 | +39.21% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $1.71 | -41.52% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.56 | -18.22% | 5 | Aug 20, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $193 → $192 | $154.38 | +24.37% | 4 | Jul 22, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $22.91 | +83.33% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $8.61 | +39.37% | 5 | Mar 5, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $7.11 | +251.62% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.80 | +511.11% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.27 | +83.49% | 2 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $2.83 | +430.04% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $44.70 | +23.04% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $31.99 | -81.24% | 2 | Dec 29, 2022 |
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $4.85
Upside: +44.33%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $8.62
Upside: +39.21%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $1.71
Upside: -41.52%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.56
Upside: -18.22%
Krystal Biotech
Jul 22, 2025
Maintains: Buy
Price Target: $193 → $192
Current: $154.38
Upside: +24.37%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $22.91
Upside: +83.33%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.61
Upside: +39.37%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $7.11
Upside: +251.62%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.80
Upside: +511.11%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.27
Upside: +83.49%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.83
Upside: +430.04%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $44.70
Upside: +23.04%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $31.99
Upside: -81.24%